Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » .11 and Up! » ACTC--NEWS (Page 4)

 - UBBFriend: Email this page to someone!   This topic comprises 8 pages: 1  2  3  4  5  6  7  8   
Author Topic: ACTC--NEWS
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
News for 'ACTC' - (NIH Announces Advanced Cell Technology's 'Single Cell Embryo Biopsy Technique' as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding ACT Applauds NIH Plan to Implement President Bush's Stem Cell Executive Order)


LOS ANGELES, Sept 20, 2007 /PRNewswire-FirstCall via COMTEX/ -- (OTC Bulletin
Board: ACTC) On Tuesday, September 18, 2007, the National Institutes of Health
(NIH) announced that it would begin implementing President George W. Bush's Executive Order to explore methods to expand the number of approved pluripotent stem cell lines "without creating a human embryo for research purposes or destroying, discarding, or subjecting to harm a human embryo or fetus."

This announcement follows an Executive Order issued by President Bush on June 20, 2007, requiring that "The Secretary of Health and Human Services ... conduct and support research on the isolation, derivation, production, and testing of stem cells that are capable of producing all or almost all of the cell types of the developing body and may result in improved understanding of or treatments for diseases and other adverse health conditions, but are derived without creating a human embryo for research purposes or destroying, discarding, or subjecting to harm a human embryo or fetus."

ACT's groundbreaking Single Cell Biopsy technique was cited by the NIH as an alternative method in its implementation plan -- a technique successfully demonstrated by Robert Lanza, M.D., Vice President of Research and Scientific Development at Advanced Cell Technology, and his team. The NIH plan calls for "aggressively pursuing an assessment of the potential of alternative sources of pluripotent stem cell lines, including altered nuclear transfer; single cell embryo biopsy, and reprogramming, or dedifferentiation of somatic cells, such as skin cells."

In August 2006, ACT published a paper in Nature documenting the technique for removing a single cell (known as a blastomere) from an eight-cell human embryo, and using that cell to generate multiple human embryonic stem cells without destroying the embryo. The NIH referred to ACT's Nature article in its implementation plan. In June of this year, ACT announced that it had successfully produced 4 human embryonic stem cell lines without destroying the embryos at its lab in Worcester, Massachusetts. The embryo from which the cell was removed remains cryogenically preserved and remains a viable embryo. Should the company's blastomere technique satisfy NIH qualifications, ACT could qualify for federal funding from the NIH.

"Our single cell blastomere technology directly addresses the President's ethical concerns and, unlike the other potential solutions described in the order, is available today. We are encouraged by the NIH's willingness to explore ways to increase the federally approved stem cell lines available and hope they will consider our technique for federal funding," remarked William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology. "We believe that such consideration reflects the will of the American people to bring novel therapies derived from stem cell research to patients with few or no alternatives."

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.

For more information, visit http://www.advancedcell.com

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar
expressions) should also be considered to be forward- looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements,
including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

SOURCE Advanced Cell Technology, Inc.


URL: http://www.advancedcell.com/

www.prnewswire.com

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
building a lil bit eh?

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
[Big Grin] [Big Grin] [Big Grin] [Big Grin] [Big Grin] [Big Grin]

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
NIH Announces Advanced Cell Technology's 'Single Cell Embryo Biopsy Technique' as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding

Sep 20, 2007 09:00:00 (ET)


LOS ANGELES, Sept 20, 2007 /PRNewswire-FirstCall via COMTEX/ -- (ACTC, Trade ) On Tuesday, September 18, 2007, the National Institutes of Health (NIH) announced that it would begin implementing President George W. Bush's Executive Order to explore methods to expand the number of approved pluripotent stem cell lines "without creating a human embryo for research purposes or destroying, discarding, or subjecting to harm a human embryo or fetus."

This announcement follows an Executive Order issued by President Bush on June 20, 2007, requiring that "The Secretary of Health and Human Services ... conduct and support research on the isolation, derivation, production, and testing of stem cells that are capable of producing all or almost all of the cell types of the developing body and may result in improved understanding of or treatments for diseases and other adverse health conditions, but are derived without creating a human embryo for research purposes or destroying, discarding, or subjecting to harm a human embryo or fetus."

ACT's groundbreaking Single Cell Biopsy technique was cited by the NIH as an alternative method in its implementation plan -- a technique successfully demonstrated by Robert Lanza, M.D., Vice President of Research and Scientific Development at Advanced Cell Technology, and his team. The NIH plan calls for "aggressively pursuing an assessment of the potential of alternative sources of pluripotent stem cell lines, including altered nuclear transfer; single cell embryo biopsy, and reprogramming, or dedifferentiation of somatic cells, such as skin cells."

In August 2006, ACT published a paper in Nature documenting the technique for removing a single cell (known as a blastomere) from an eight-cell human embryo, and using that cell to generate multiple human embryonic stem cells without destroying the embryo. The NIH referred to ACT's Nature article in its implementation plan. In June of this year, ACT announced that it had successfully produced 4 human embryonic stem cell lines without destroying the embryos at its lab in Worcester, Massachusetts. The embryo from which the cell was removed remains cryogenically preserved and remains a viable embryo. Should the company's blastomere technique satisfy NIH qualifications, ACT could qualify for federal funding from the NIH.

"Our single cell blastomere technology directly addresses the President's ethical concerns and, unlike the other potential solutions described in the order, is available today. We are encouraged by the NIH's willingness to explore ways to increase the federally approved stem cell lines available and hope they will consider our technique for federal funding," remarked William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology. "We believe that such consideration reflects the will of the American people to bring novel therapies derived from stem cell research to patients with few or no alternatives."

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.

For more information, visit http://www.advancedcell.com

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward- looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

SOURCE Advanced Cell Technology, Inc.




http://www.advancedcell.com/

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
copy cat lol


Advanced Cell Technology Inc (OTCBB: ACTC) up 7.4% on 1.5 million shares traded.

Advanced Cell Technology Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
I LIKE WHAT IM SEEING BOO!

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
mR. pEABODY IS LEAVIN bUT i STILL LIKE IT TOO!

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
keep hittin it! go away nite!!

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
News for 'ACTC' - (Advanced Cell Technology Completes Acquisition of Mytogen, Inc. Transaction Significantly Accelerates Stem Cell Clinical Development Activities; Phase II Clinical Trials to Begin Shortly)


LOS ANGELES, Sep 24, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.
(OTCBB: ACTC) today announced that it has completed the acquisition of all of the outstanding capital stock of Mytogen, Inc. In May 2007, the company announced that it had entered into a letter of intent to acquire Mytogen, Inc.
and its Myoblast Program for the treatment of heart failure. A definite merger agreement was signed on July 31, 2007 subject to certain closing conditions.
ACTC issued a total of approximately 8.2 million restricted shares of common stock, valued at $5 million and assumed certain Mytogen liabilities. Mytogen shareholders also received a warrant to purchase an additional 1.5 million shares of restricted common stock at $0.75 per share subject to the achievement of certain milestones.

Mytogen brings to the company over ten years of experience in clinical trial and FDA experience in developing and advancing cellular therapies including the use of stem cells. This stem cell therapy involves transplantation of expanded autologous myoblasts (adult progenitor stem cells) derived from a small biopsy of skeletal muscle from a patient's leg. The technology allows for the expansion of myoblasts into hundreds of millions of cells over a period of two to three weeks. The resulting myoblasts are then transplanted back into the patient's scarred heart tissue through the use of a catheter-based procedure. The Myoblast Program has successfully completed Phase I human clinical trials using the myoblast platform, utilizing the therapy safely in over 40 patients. Safety of the company's myoblast therapy has been demonstrated in four independent studies. While the Phase I human clinical trials were focused on the safety of the therapy, the clinical data from those trials suggests that the myoblasts often improve function in the heart and may lead to a significant increase in quality of life for the patient. The company applied its myoblast therapy without the use of accompanying arrhythmia preventatives mandated by the FDA for similar programs. The FDA has reviewed the "end-of-Phase I" data and will allow Advanced Cell Technology to proceed with a Phase II human clinical trial.

The company plans to begin the Phase II human clinical trial for the treatment of heart failure in approximately 160 patients. If successful, the company expects to proceed with a pivotal Phase III trial. The Myoblast Program may prove particularly beneficial for patients that have experienced a serious heart attack and have a high risk of heart failure.

"Advanced Cell Technology has always been on the cutting edge of regenerative medicine and we are excited to join their team," noted Dr. Jonathan Dinsmore, President and Chief Scientific Officer of Mytogen, Inc. "By merging with Advanced Cell, we can now move forward with our clinical trials and bring our therapies to cardiac patients in need of this novel treatment."

William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology remarked, "The completion of this acquisition marks a transformation for our company, as it significantly advances our clinical development activities, placing the company among the most clinically advanced stem cell companies. We now have three distinct programs in various stages of clinical and preclinical development. Our Myoblast Program for the treatment of heart failure will begin Phase II clinical trials shortly, while two of our human embryonic stem cell programs, our Hemangioblast Program for treating blood and cardiovascular disease and our RPE Program for treating retinal degenerative disorders, are in preclinical studies. We expect to file IND's for those programs next year."

Additional details regarding the definitive merger agreement with Mytogen are included in a Current Report on Form 8-K filed by the Company on August 6, 2007, with the Securities and Exchange Commission.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.

For more information, visit www.advancedcell.com

About Mytogen, Inc.

Mytogen, Inc. is a Massachusetts based company developing autologous myoblast transplantation designed to restore cardiac function in patients with heart failure. The incidence and progressive nature of heart disease make it the leading cause of morbidity and mortality in the U.S. Mytogen is advancing a proprietary formulation of cultured human myoblasts and an optimized delivery system to deliver cells to the site of cardiac damage. Mytogen represents the consolidation of experts in areas including clinical manufacturing of biologics, cell transplantation, and stem cell biology and benefits from intellectual property assets and clinical trial experience acquired from Genvec and Diacrin, Inc. Currently, Mytogen is conducting U.S. human clinical trials of its myoblast therapy with FDA oversight, and is positioned to launch multi-center phase II studies in the near future.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar
expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements,
including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

SOURCE: Advanced Cell Technology, Inc.


CONTACT: Chad Griffin Consulting, Inc.Jordan Markwith, 310-888-3523orInvestors:CEOcast, Inc.Andrew Hellman, 212-732-4300


Copyright Business Wire 2007

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
time to get back to that $1

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
SEEMS LIKE WE HAVE STRONGER SUPPORT NOW.JMO

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
PPS .30

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
juice
Member


Rate Member
Icon 1 posted      Profile for juice         Edit/Delete Post   Reply With Quote 
see lots of form 144's over the last few months...is ACTC toast?

CRANSHIRE CAPITAL L.P. IL 9/21/2007 Form 144 221,545 55,555 N/A / N/A
BRISTOL INVESTMENT FUND LTD. VGB 9/21/2007 Form 144 44,849 12,782 N/A / N/A
OVERBROOK FUND 1, LLC NY 9/20/2007 Form 144 626,210 175,338 N/A / N/A
JGB CAPITAL LP SHR NY 9/20/2007 Form 144 626,210 175,338 N/A / N/A
GOLDMAN, JAY MASTER LIMITED PARTNERSHIP NY 9/18/2007 Form 144 439,385 123,027 N/A / N/A
ROCKMORE INVESTMENT MASTER FD LTD. NY 9/18/2007 Form 144 27,610 7,454 N/A / N/A
JMB CAPITAL PARTNERS MASTER FUND, LP CA 9/12/2007 Form 144 626,210 187,863 N/A / N/A
JMG TRITON OFFSHORE FUND, LTD. CA 9/12/2007 Form 144 150,000 42,000 N/A / N/A
JMG CAPITAL PARTNERS, LP CA 9/12/2007 Form 144 155,000 42,000 N/A / N/A
ARONSON, GARY D. NV 9/12/2007 Form 144 13,175 3,623 N/A / N/A
NEWBERG FAMILY TRUST UTD 12/18/90 CA 9/11/2007 Form 144 350,000 105,000 N/A / N/A
RUNNELS FAMILY TRUST DTD 1/11/2000 CA 9/11/2007 Form 144 231,710 69,513 N/A / N/A
HIGH TIDE, LLC CA 9/11/2007 Form 144 231,710 69,513 N/A / N/A
MM&B HOLDINGS, A CALIFORNIA GENERAL PARTNERSHIP CA 9/11/2007 Form 144 525,000 157,200 N/A / N/A
PROFITSIDE GROWTH AND OPPORTUNITY FUND SHR NY 9/10/2007 Form 144 298,000 87,910 N/A / N/A
PORTSIDE GROWTH AND OPPORTUNITY FUND SHR NY 9/10/2007 Form 144 298,000 87,910 N/A / N/A
SMITHFIELD FIDUCIARY LLC NY 9/7/2007 Form 144 626,210 184,731 N/A / N/A
BRISTOL INVESTMENT FUND LTD. VGB 9/7/2007 Form 144 235,000 69,325 N/A / N/A
BRISTOL INVESTMENT FUND LTD. VGB 9/6/2007 Form 144 200,000 62,000 N/A / N/A
SHAPIRO, ALAN C. DIR CA 9/6/2007 Form 4 JB 17,431 $0.240 Indirect / Indirect 333,396
SHAPIRO, ALAN C. DIR CA 9/4/2007 Form 4 JB 28,851 $0.290 Indirect / Indirect 315,965
GOLDMAN, JAY MSTR LP NY 9/4/2007 Form 144 626,210 225,435 N/A / N/A
NEWBERG FAMILY TRUST UTD 12/18/90 CA 8/23/2007 Form 144 41,013 13,124 N/A / N/A
ARONSON, GARY D. NV 8/21/2007 Form 144 120,394 35,757 N/A / N/A
BRISTOL INVESTMENT FUND LTD. VGB 8/16/2007 Form 144 149,015 44,705 N/A / N/A
PORTSIDE GROWTH AND OPPORTUNITY FUND SHR NY 8/10/2007 Form 144 312,000 118,560 N/A / N/A
JMG CAPITAL PARTNERS, LP CA 8/8/2007 Form 144 235,000 94,000 N/A / N/A
ARONSON, GARY D. NV 8/2/2007 Form 144 65,505 23,582 N/A / N/A
SHAPIRO, ALAN C. DIR CA 8/1/2007 Form 4 JB 24,608 $0.340 Indirect / Indirect 287,114
GORTON, JOHN S. SEPARATE PROPERTY TRUST CA 7/27/2007 Form 144 50,000 18,500 N/A / N/A
ARONSON, GARY D. NV 7/12/2007 Form 144 58,000 27,550 N/A / N/A
ARONSON, GARY D. NV 7/10/2007 Form 144 125,000 59,375 N/A / N/A
JMG CAPITAL PARTNERS, LP CA 7/9/2007 Form 144 150,000 72,000 N/A / N/A
JMG TRITON OFFSHORE FUND, LTD. CA 7/9/2007 Form 144 150,000 72,000 N/A / N/A
BRISTOL INVESTMENT FUND LTD. VGB 7/6/2007 Form 144 135,455 64,341 N/A / N/A
ARONSON, GARY D. NV 7/5/2007 Form 144 223,816 100,717 N/A / N/A
SHAPIRO, ALAN C. DIR CA 7/2/2007 Form 4 JB 16,405 $0.510 Indirect / Indirect 262,506
GORTON, JOHN S. SEPARATE PROPERTY TRUST CA 7/2/2007 Form 144 50,000 22,500 N/A / N/A
MM&B HOLDINGS, A CALIFORNIA GENERAL PARTNERSHIP CA 6/20/2007 Form 144 100,420 66,277 N/A / N/A
GORTON, JOHN S. SEPARATE PROPERTY TRUST CA 6/18/2007 Form 144 30,000 19,200 N/A / N/A
ARONSON, GARY D. NV 6/14/2007 Form 144 33,495 23,949 N/A / N/A
PORTSIDE GROWTH AND OPPORTUNITY FUND SHR NY 6/7/2007 Form 144 295,000 203,550 N/A / N/A
SHAPIRO, ALAN C. DIR CA 6/1/2007 Form 4 JB 14,425 $0.580 Indirect / Indirect 246,101
BRISTOL INVESTMENT FUND LTD. VGB 6/1/2007 Form 144 95,206 144,253 N/A / N/A
BRISTOL INVESTMENT FUND LTD. VGB 6/1/2007 Form 144 144,253 95,207 N/A / N/A
SMITHFIELD FIDUCIARY LLC NY 6/1/2007 Form 144 26,063 23,440 N/A / N/A
BRISTOL INVESTMENT FUND LTD. VGB 5/10/2007 Form 144 173,535 121,474 N/A / N/A
SMITHFIELD FIDUCIARY LLC NY 5/3/2007 Form 144 34,350 22,327 N/A / N/A
JMG TRITON OFFSHORE FUND, LTD. CA 5/2/2007 Form 144 200,012 130,007 N/A / N/A

Posts: 2794 | From: nyc | Registered: Aug 2005  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
Convertibles.

Toast? I highly doubt it. JMO.

Would be nice to see some decent projections or study status news to absorb some of the conversions.

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
juice
Member


Rate Member
Icon 1 posted      Profile for juice         Edit/Delete Post   Reply With Quote 
gotcha, thanks boodog.
Posts: 2794 | From: nyc | Registered: Aug 2005  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
Cheers

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
quote:
Originally posted by BooDog:
Convertibles.

Toast? I highly doubt it. JMO.

Would be nice to see some decent projections or study status news to absorb some of the conversions.

Dude...

News for 'ACTC' - (BioTime Names Dr. Michael D. West as CEO and Announces Entry Into Stem Cell Research and Regenerative Medicine)


EMERYVILLE, Calif., Oct 11, 2007 (BUSINESS WIRE) -- BioTime, Inc. (OTCBB:BTIM) today announced that Michael D. West, Ph.D. has become BioTime's new Chief Executive Officer. Dr. West will help spearhead BioTime's entry into the field of regenerative medicine by developing advanced human stem cell products and technology for diagnostic, therapeutic and research use.

Dr. West, who has served on the BioTime Board of Directors since 2002, has played a pioneering role in organizing the original collaborative effort to isolate human embryonic stem cells and in cloning and stem cell research. He has extensive academic and business experience in age-related degenerative diseases, telomerase molecular biology and human embryonic stem cell research and development. Prior to joining BioTime, Dr. West served as Director, President and Chief Scientific Officer of Advanced Cell Technology, Inc., a company engaged in developing human stem cell technology for use in regenerative medicine. Prior to Advanced Cell Technology, Inc., Dr. West founded Geron Corporation where he initiated and managed programs in telomerase diagnostics, telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase to immortalize human cells. He is an inventor named on over 60 patents and patent applications in the field of biotechnology and is an Adjunct Professor of Bioengineering at the University of California, Berkeley. Dr. West received a B.S. Degree from Rensselaer Polytechnic Institute in 1976, an M.S.
Degree in Biology from Andrews University in 1982, and a Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging.

"The timing is right for important new business opportunities in the emerging field of regenerative medicine and stem cell research," said Michael D. West, Ph.D., BioTime's new Chief Executive Officer. "I couldn't be more enthusiastic about working with BioTime's experienced team, that has successfully navigated a therapeutic product, Hextend(R), through regulatory approval, and has brought its second product, PentaLyte(R), through a Phase II clinical trial. BioTime's goal will be to expand its research and development efforts into the new field of regenerative medicine, while continuing to develop and create markets for its line of blood plasma volume expander products."

Regenerative medicine refers to therapies based on human embryonic stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. Embryonic stem cells are the first cells ever discovered that are capable of infinite cell division while possessing the potential to differentiate into all of the cell types of the human body. Stem cells may also have commercial uses in the development of experimental new drugs.

"We are very excited to have Dr. West join BioTime as our new CEO," says Dr. Hal Sternberg, VP Research, and Member Office of the President. "We expect that his leadership capabilities and great expertise in human embryonic stem cell technology will enable BioTime to develop important innovative products for this rapidly expanding industry."

In addition to entering this emerging field of medicine, BioTime will continue to seek new markets for its physiologically balanced blood plasma volume expander products. BioTime's lead product, Hextend(R), is distributed in the United States and South Korea and is undergoing clinical trials in Japan, while BioTime is continuing to offer licensing rights to Hextend in other countries.
Hextend has become the standard plasma volume expander at a number of prominent teaching hospitals and leading medical centers and is part of the United States Armed Forces Tactical Combat Casualty Care protocol. PentaLyte(R) has undergone Phase II clinical testing in the United States and BioTime is now offering pharmaceutical companies in the U.S. and abroad the opportunity to license PentaLyte(R).

BioTime plans to seek up to $5,000,000 of new funding to finance its operations and its entry into the stem cell field. BioTime has not yet determined the amount or terms of any securities that may be offered in connection with such financing. Any securities that may be offered have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.

BioTime also plans to apply for research funding grants from private and public sources, including the California Institute for Regenerative Medicine ("CIRM").
CIRM was established in early 2005 with the passage of Proposition 71, the California Stem Cell Research and Cures Initiative. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was approved by California voters on November 2, 2004, and called for the establishment of a new state agency to make grants and provide loans for stem cell research, research facilities and other vital research opportunities. CIRM will use bond proceeds to fund basic and applied biomedical research focused on developing diagnostics and therapies and on other vital research opportunities that will lead to life-saving medical treatments. All proposals are peer-reviewed to support the most promising scientific research. Research grants are made only to California-based research institutions.

About BioTime, Inc.

BioTime, headquartered in Emeryville, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ Corp. under exclusive licensing agreements. BioTime has recently entered the field of regenerative medicine where it plans to develop new medical and research products using embryonic stem cell technology.
Information about BioTime can be found on the web at www.biotimeinc.com.
Hextend(R) and PentaLyte(R) are registered trademarks of BioTime, Inc.

Forward Looking Statements

The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the success of BioTime in developing new stem cell products and technologies; results of clinical trials of BioTime products; the ability of BioTime and its licensees to obtain additional FDA and foreign regulatory approval to market BioTime products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime products, and the ability of BioTime to raise the capital needed to finance its current and planned operations. Other factors that could affect BioTime's operations and financial condition are discussed in BioTime's Annual Report on Form 10-KSB filed with the Securities and Exchange Commission.

SOURCE: BioTime, Inc.


CONTACT: BioTime, Inc.Judith Segall, 510-350-2940


Copyright Business Wire 2007

-0-


KEYWORD: United States

North America

California

INDUSTRY KEYWORD: Health

Biotechnology

Clinical Trials

--------------------------------------------
AND [Big Grin]
--------------------------------------------
News for 'ACTC' - (Advanced Cell Technology Announces the Promotion of Dr. Robert Lanza to Chief Scientific Officer Dr. Michael West Transitions to Non-Executive Director)


LOS ANGELES, Oct 11, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.
(OTCBB: ACTC) today announced the promotion of Dr. Robert Lanza, M.D., to the position of Chief Scientific Officer. Dr. Lanza joined Advanced Cell Technology in 1999 and has developed and managed several of the company's human embryonic stem cell (hESC) research programs including, but not limited to, the Retinal Pigment Epithelial (RPE) Cell Program, the Hemangioblast (HG) Cell Program and the Somatic Cell Nuclear Transfer (SCNT) research. Dr. Lanza will continue to work closely with Dr. Pedro Huertas, M.D., Ph.D., ACT's Chief Development Officer, to drive these hESC therapies to the clinical development stage. The company expects to file INDs for its RPE and HG Programs in 2008.

Moreover, with the acquisition of Mytogen, Dr. Huertas and Dr. Lanza together with Dr. Jonathan Dinsmore, Ph.D., expect ACT's Myoblast Program, an adult autologous stem cell therapy for the treatment of heart failure, to begin Phase II human clinical trials shortly, after having successfully completed four Phase I human clinical trials. Dr. Nabil Dib, an interventional cardiologist at University of California at San Diego's School of Medicine, will serve as a consultant to the company and lead the cellular transplantation process which is at the center of the Myoblast Program clinical trials.

"We are excited to elevate Dr. Lanza to this position after his contributions to the company and look forward to his leadership and guidance," stated William M.
Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "Following the acquisition of Mytogen, Inc., we have streamlined this company to more effectively and expeditiously move our stem cell therapies from the research stage to the clinical trial phase of development. We believe the combination of Dr. Lanza, Dr. Huertas and Dr. Dinsmore provide us with a world-class research and development team."

Dr. Lanza has over 25 years of research and industrial experience in stem cell research and regenerative medicine. From 1990 to 1998, he was Director of Transplantation Biology at BioHybrid Technologies, Inc., and is currently an Adjunct Professor at the Institute for Regenerative Medicine at Wake Forest University School of Medicine. Dr. Lanza has several hundred scientific publications and patents, and has authored and/or edited 20 books, including the Handbook of Stem Cells (as Editor-in-Chief), Principles of Tissue Engineering, XENO, Yearbook of Cell & Tissue Transplantation, and One World: The Health & Survival of the Human Species in the 21st Century (as editor, with forewords by C. Everett Koop and former President Jimmy Carter). He is a former Fulbright Scholar, and studied as a student in the laboratories of Richard Hynes (MIT), Jonas Salk (The Salk Institute), and Nobel laureates Gerald Edelman (Rockefeller
University) and Rodney Porter (Oxford University). Dr. Lanza also worked closely and coauthored a series of papers with the late Harvard psychologist B.F.
Skinner and heart transplant pioneer Christiaan Barnard. Dr. Lanza received his B.A. and M.D. degrees from the University of Pennsylvania, where he was both a University Scholar and Benjamin Franklin Scholar.

Simultaneous with Dr. Lanza's promotion, Advanced Cell Technology has announced that Michael D. West, Ph.D., is voluntarily stepping down as the company's President and Chief Scientific Officer to pursue new opportunities primarily relating to continued research on the ACTcellerate technology platform, which was exclusively developed by Dr. West. The company is in current discussions with several companies to license the ACTcellerate technology program. Dr. West will remain as a director of the company and has entered into a consulting arrangement through the end of 2007 to assist the company with certain scientific and intellectual property projects. "On behalf of the company, the board of directors, and the employees at Advanced Cell Technology, we want to thank Dr. West for his dedication and leadership and for all of the contributions he has made both to our company as well to the field of regenerative medicine." stated Mr. Caldwell.

"I look forward to working with ACT in my consulting capacity to help move the first embryonic stem cell-derived products into the clinic," said Dr. Michael West.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.

For more information, visit www.advancedcell.com

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar
expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements,
including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

SOURCE: Advanced Cell Technology, Inc.


CONTACT: Media:Chad Griffin Consulting, Inc.Jordan Markwith, 310-888-3523orInvestors:CEOcast, Inc.Andrew Hellman, 212-732-4300


Copyright Business Wire 2007

-0-


KEYWORD: United States

North America

California

Massachusetts

INDUSTRY KEYWORD: Health

Biotechnology


You might think they read my post. lol [Eek!] [Cool] [Big Grin]

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
LOL, MAYBE BOO. [Eek!]

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
Related Quotes
Sym. Price Chg.
ACTC Trade
News 0.295 0.017
ACT's Myoblast Trial Selected as Late Breaking Trial for AHA Conference

Oct 16, 2007 08:59:03 (ET)


LOS ANGELES, Oct 16, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) today announced that the American Heart Association (AHA) has selected the company's Myoblast Phase I(b) trial as a featured late breaking trial for its annual Scientific Sessions Conference in Orlando Florida on November 4, 2007 through November 7, 2007. The AHA's Scientific Sessions Conference is among the premier cardiovascular research and instructional meetings worldwide bringing together interventional cardiologists, electrophysiologists, and nurses and other professionals with content from the forefront of research and clinical practice, including more than 4,000 abstracts of original research and a variety of invited programs. In addition, an International Congress on Stem Cells and Myocardial Regeneration will run concurrently with Scientific Sessions, featuring the most internationally renowned investigators in the field.

Advanced Cell Technology's myoblast therapy (acquired via its acquisition of Mytogen, Inc.) involves the transplantation of expanded autologous myoblasts (adult progenitor stem cells) derived from a small biopsy of skeletal muscle from a patient's leg. The technology allows for the expansion of myoblasts into hundreds of millions of cells over a period of two to three weeks. The resulting myoblasts are then transplanted back into the patient's scarred heart tissue through the use of a 3-D electromechanical mapping based-catheter procedure, which differs from a number of competitive therapies that may require open heart surgery or a less precise catheter-based system to deliver new cells. Since ACT's technology has never necessitated the use of accompanying arrhythmia preventatives usually required for similar programs, ACT will be permitted to conduct its Phase II trials without anti-arrhythmia precautions as well. The FDA has required studies of competitive therapies to use anti-arrhythmia medications and/or implanted defibrillators because of the safety risks involved with those treatments. In contrast, because of ACT's positive safety record with its Myoblast Program, the FDA has not put such restrictions on the ACT myoblast therapy.

"We have spent many years of research devoted to making our myoblast product the safest and most effective in the industry," noted Dr. Jonathan Dinsmore, Ph.D., Vice President and General Manager at Advanced Cell Technology. "It is gratifying to see that work translate into positive, clinical safety and survival data."

The Myoblast Program has successfully completed Phase I human clinical trials utilizing the therapy safely in over forty patients. Safety of the company's myoblast therapy has been demonstrated in four independent studies, all conducted under FDA oversight. The FDA has reviewed the "end-of-Phase I" data and will allow Advanced Cell Technology to proceed with a Phase II human clinical trial. The company plans to begin the Phase II human clinical trial for the treatment of heart failure in approximately 160 patients. Dr. Nabil Dib, an interventional cardiologist at University of California at San Diego's School of Medicine, will serve as a consultant to the company and lead the cellular transplantation team to advance the Myoblast Program clinical efficacy trials. If the Phase II human clinical trials are successful, the company expects to proceed with a pivotal Phase III trial. The Myoblast Program may prove particularly beneficial for patients that have experienced a serious heart attack and have a high risk of heart failure.

William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology commented, "We are delighted that the American Heart Association has recognized the potential for our Myoblast Program to effectively treat patients with heart failure via its inclusion of the study in its November conference. We look forward to moving into Phase II human clinical trials and ultimately bringing this and other stem cell therapies to the bedside."

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.

For more information, visit www.advancedcell.com

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

SOURCE: Advanced Cell Technology, Inc.


Media:
Chad Griffin Consulting, Inc.
Jordan Markwith, 310-888-3523
or
Investors:
CEOcast, Inc.
Andrew Hellman, 212-732-4300

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
HEYYYYYY!! you beat me!

Advanced Cell Technology, Inc. (ACTC, Trade ) today announced that the American Heart Association (AHA) has selected the company's Myoblast Phase I(b) trial as a featured late breaking trial for its annual Scientific Sessions Conference in Orlando Florida on November 4, 2007 through November 7, 2007.


[Big Grin] SWEEEEEEET [Big Grin]

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
[Razz] [Razz] [Razz] [Razz] [Razz] [Razz] [Razz]

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
Research and Markets: New Company Profile Analyses (ACTC) Advanced Cell Technology Inc

Oct 17, 2007 12:00:01 (ET)


DUBLIN, Ireland, Oct 17, 2007 (BUSINESS WIRE) -- Research and Markets ( http://www.researchandmarkets.com/reports/c71679 ) has announced the addition of (ACTC)ADVANCED CELL TECHNOLOGY INC - Quantitative Valuation Report to their offering.

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and useful report available. Our three models: Valuation Model, Forecast Model and Ratings Model are incorporated to give you a well-rounded analysis from three different perspectives. Consensus EPS trend and Earnings Surprise statistics provide additional insights. Also, detailed Company Profile, Fair Valuation; 1-3-6 month and 1-2-3 yr forecasts, 1-5 Engine Rating, Multi-stock comparison, Financials, Earnings Estimates, Risk Assessment, Data Summary and much more.

Each of our Quantitative Valuation reports Provides:

-- Overview

-- Our Rating

-- Fair Value

-- Investment-Style Rating

-- Return Forecasts

-- Market Ratio-Based Valuation

-- Quantitative Summary

-- Comparisons

-- Earnings Report

-- Analyst Expectations

-- Annual Financials

-- Quarterly Financial

Independent, numbers-based, objective Equity Research

Use this report to help to:

-- Optimize your equity portfolio for the best risk/return ratio.

-- Forecast equity portfolios value next year.

-- Find a fair value for stocks and forecast their future prospects.

-- Determine the chances of gain or loss on current holdings.

-- Find momentum & volatility ranks for stocks.

Our valuation reports are updated on each trading date.

Yale finance professor Dr. Zhiwu Chen has done an excellent job of transforming academic research and rigorous mathematics into a practical investing tool. The valuation model combines 12-month trailing EPS, consensus analyst estimates, and the 30-year Treasury yield to come up with a fair value price for any stock. Then its forecast model uses common market trends such as momentum and price reversals, and runs simulations to determine the most probable price outcomes over three years. - Forbes

For more information visit http://www.researchandmarkets.com/reports/c71679

SOURCE: Research and Markets Ltd.


Research and Markets
Laura Wood
Senior Manager
Fax: +353 1 4100 980
press*researchandmarkets.com

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
dagumit. My alerts must be off. where'd you find that IMAKE?? tia

Looks like you have to pay for it if you want it. Do you use these guys with any reliability? I think we can draw our own opinions these days with all the internet resources. Why pay for it if you don't havta??

Anyway, just wondering how you came about it.

cheers

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
BUSINESS WIRE) BOO

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
roger that. I saw it finally.

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
By: mailman2007
17 Oct 2007, 07:20 PM EDT
Msg. 3508 of 3510
Jump to msg. #
Dinsmore has plans for the heart of the initiativeMass High Tech: The Journal of New England Technology - by Lloyd Gray Mass High Tech
Print Article Email Article Reprints RSS Feeds Add to Del.icio.us Digg This
Though the picture in his mind was a wee bit fuzzy back then, Jonathan Dinsmore pretty much knew at age 10 what he wanted to be when he grew up. With a strong interest in science and biology, the leading choices were medical doctor, veterinarian, or medical researcher.

"It was going to be (one of) those, but it was a moving target," he said recently with a chuckle.

Several years, pedigreed schools and hard-earned degrees later, Dinsmore is now president, director and chief scientific officer of Mytogen Inc.

Based in Charlestown and privately held, Mytogen develops cell-therapy products using stem cells. Its employees comprise experts specializing in clinical manufacturing of biologics, cell transplantation, and stem cell biology.

Most of the attention the company receives these days is for its patented work using myoblasts -- also known as stem cells that form muscle -- to treat patients with congestive heart failure.

After completing an initial safety and feasibility clinical trial, Mytogen, with U.S. Food and Drug Administration clearance, is now set to begin a second phase, this one aimed at confirming the initial results.

Dinsmore estimates that with 5 million U.S. citizens experiencing heart complications, and with 500,000 new cases being diagnosed each year, market potential is in the billions.

That potential led Advanced Cell Technology Inc. -- a company with locations in Worcester and Alameda, Cailf. -- to buy Mytogen for about $6 million.

Executives from ACT, which has most of research operations in Worcester, have been meeting with Bay State Lt. Gov. Tim Murray to discuss how the developer of stem cell treatments could take advantage of a state plan to invest $1 billion in the life sciences sector, said the company's CEO William Caldwell.

i found the link...
http://cincinnati.bizjournals.com/masshightech/stories/2007/09/10/focus4.html

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
Lookin better!
[Big Grin]

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
.31

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
breadwinner
Member


Member Rated:
4
Icon 1 posted      Profile for breadwinner     Send New Private Message       Edit/Delete Post   Reply With Quote 
This stock has been consolidating for 8 weeks now. I think we'll see a move to the upside sooner than later. Selling has definetly dried up, just need new buyers before this takes off. Looks good from here.
Posts: 79 | From: California | Registered: Sep 2005  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
Advanced Cell Presents Phase I(b) Data Demonstrating Safety and Optimal Dosage for Myoblast Program at TCT Conference and Exposition

Oct 25, 2007 07:33:01 (ET)


LOS ANGELES, Oct 25, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that Dr. Nabil Dib presented interim, 6 month safety and dosage data for ACT's Myoblast Phase I(b) Program at TCT 2007 - the Transcatheter Cardiovascular Therapeutic Conference and Exposition, in Washington D.C. from October 20-25, 2007. TCT is one of the leading conferences for the field of interventional cardiology. The interim data showed myoblast safety, with no evidence for increased risk of arrhythmia. The safety data presented by Dr. Dib distinguish the ACT Myoblast Program, which in contrast to other clinical programs does not require the use anti-arrhythmia medications and/or an implanted defibrillator device.

Further, as noted by Dr. Dib, the current study provides support for the hypothesis that myoblasts can help repair scarred myocardium. This was achieved by use of a control group and echocardiology core lab analysis. Dr. Dib presented the six-month interim data at "Interventional Heart Failure II: Endovascular and Surgical Approaches Session IV: Abstract session-therapeutics in heart failure. "I am pleased that we were selected to participate in this high-profile event," said Dr. Jonathan Dinsmore, Ph.D. "Our highly experienced clinical and cell manufacturing teams have demonstrated that through years of research we have achieved a superior safety profile enabling us to conduct all of our trials without the need for assist devices or arrhythmia preventative drugs. Our continuing safety results should provide for the most effective development of the myoblast technology through upcoming larger efficacy studies."

TCT 2007 is the essential gathering place for physicians, allied healthcare professionals, academics, and regulators to review critically and openly the status of cardiovascular intervention and to chart pathways to further improve outcomes for patients with coronary, endovascular, and structural heart disease.

Advanced Cell Technology's myoblast therapy (acquired via its acquisition of Mytogen, Inc.) involves the transplantation of expanded autologous myoblasts (adult progenitor stem cells) derived from a small biopsy of skeletal muscle from a patient's leg. The technology allows for the expansion of myoblasts into hundreds of millions of cells over a period of two to three weeks. The resulting myoblasts are then transplanted back into the patient's scarred heart tissue through the use of a 3-D electromechanical mapping based-catheter procedure, which differs from a number of competitive therapies that may require open heart surgery or a less precise catheter-based system to deliver new cells.

About TCT 2007

With rapid changes occurring in the field of interventional vascular medicine, TCT 2007 will be the essential gathering place for physicians, allied healthcare professionals, academics, and regulators to review critically and openly the status of cardiovascular intervention and to chart pathways to further improve outcomes for patients with coronary, endovascular, and structural heart disease.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.

For more information, visit www.advancedcell.com

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

SOURCE: Advanced Cell Technology, Inc.


Media:
Chad Griffin Consulting, Inc.
Jordan Markwith, 310-888-3523
or
Investors:
CEOcast, Inc.
Andrew Hellman, 212-732-4300

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
Advanced Cell Presents Phase I(b) Data Demonstrating Safety and Optimal Dosage for Myoblast Program at TCT Conference and Exposition

Oct 25, 2007 08:00:15 (ET)


LOS ANGELES, Oct 25, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that Dr. Nabil Dib presented interim, 6 month safety and dosage data for ACT's Myoblast Phase I(b) Program at TCT 2007 - the Transcatheter Cardiovascular Therapeutic Conference and Exposition, in Washington D.C. from October 20-25, 2007. TCT is one of the leading conferences for the field of interventional cardiology. The interim data showed myoblast safety, with no evidence for increased risk of arrhythmia. The safety data presented by Dr. Dib distinguish the ACT Myoblast Program, which in contrast to other clinical programs does not require the use anti-arrhythmia medications and/or an implanted defibrillator device. Further, as noted by Dr. Dib, the inclusion of a control group in the current study and the use of echocardiography core lab analysis for blinded assessment of effects of the myoblasts on ventricular remodeling provide support for the hypothesis that myoblasts can help repair scarred myocardium. Dr. Dib presented the six-month interim data at "Interventional Heart Failure II: Endovascular and Surgical Approaches Session IV: Abstract session-therapeutics in heart failure.. "I am pleased that we were selected to participate in this high-profile event" said Dr. Jonathan Dinsmore, Ph.D. "Our highly experienced clinical and cell manufacturing teams have demonstrated that through years of research we have achieved a superior safety profile enabling us to conduct all of our trials without the need for assist devices or arrhythmia preventative drugs. Our continuing safety results should provide for the most effective development of the myoblast technology through upcoming larger efficacy studies.

TCT 2007 is the essential gathering place for physicians, allied healthcare professionals, academics, and regulators to review critically and openly the status of cardiovascular intervention and to chart pathways to further improve outcomes for patients with coronary, endovascular, and structural heart disease.

Advanced Cell Technology's myoblast therapy (acquired via its acquisition of Mytogen, Inc.) involves the transplantation of expanded autologous myoblasts (adult progenitor stem cells) derived from a small biopsy of skeletal muscle from a patient's leg. The technology allows for the expansion of myoblasts into hundreds of millions of cells over a period of two to three weeks. The resulting myoblasts are then transplanted back into the patient's scarred heart tissue through the use of a 3-D electromechanical mapping based-catheter procedure, which differs from a number of competitive therapies that may require open heart surgery or a less precise catheter-based system to deliver new cells.

About TCT 2007

With rapid changes occurring in the field of interventional vascular medicine, TCT 2007 will be the essential gathering place for physicians, allied healthcare professionals, academics, and regulators to review critically and openly the status of cardiovascular intervention and to chart pathways to further improve outcomes for patients with coronary, endovascular, and structural heart disease.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.

For more information, visit www.advancedcell.com

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

SOURCE: Advanced Cell Technology, Inc.


Media:
Chad Griffin Consulting, Inc.
Jordan Markwith, 310-888-3523
or
Investors:
CEOcast, Inc.
Andrew Hellman, 212-732-4300

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
IMAKEMONEY
Member


Icon 1 posted      Profile for IMAKEMONEY     Send New Private Message       Edit/Delete Post   Reply With Quote 
Advanced Cell Technology's Chief Scientific Officer Delivers Keynote Address at Leading International Stem Cell Conference

Oct 31, 2007 07:08:01 (ET)


LOS ANGELES, Oct 31, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that Dr. Robert Lanza, M.D., the company's Chief Scientific Officer, delivered yesterday the keynote address at the 7th International Stem Cell Conference, a leading international stem cell conference held October 29-30th in Pittsburgh. The conference featured speakers and presenters from leading stem cell companies and academic researchers. Dr. Lanza was joined as a featured presenter by James F. Battey, Jr., M.D., Ph.D., Director - National Institute on Deafness and Other Communication Disorders.

Dr. Lanza discussed in his address Advanced Cell Technology's new technologies to address immune tolerance issues that are increasingly a focus of the stem cell industry, along with the company's single biopsy technology that was recently identified by the Department of Health and Human Services as one of the technologies that merits further evaluation for potential financial support.

Recently, Advanced Cell Technology announced that the American Heart Association (AHA) has selected the company's Myoblast Phase I(b) trial as a featured late breaking trial for its annual Scientific Sessions Conference in Orlando Florida on November 4, 2007 through November 7, 2007. The AHA's Scientific Sessions Conference is among the premier cardiovascular research and instructional meetings worldwide bringing together interventional cardiologists, electrophysiologists, and nurses and other professionals with content from the forefront of research and clinical practice, including more than 4,000 abstracts of original research and a variety of invited programs.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.

For more information, visit www.advancedcell.com

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

SOURCE: Advanced Cell Technology, Inc.


Media:
Chad Griffin Consulting, Inc.
Jordan Markwith, 310-888-3523
or
Investors:
CEOcast, Inc.
Andrew Hellman, 212-732-4300

--------------------
LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT!

Posts: 9276 | From: San Diego CA | Registered: Jul 2006  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
YES YES YES i DO like this.

Investors Overview
Advanced Cell Technology, Inc. (OTCBB:ACTC – News) is applying stem cell technology in the field of regenerative medicine to bring effective, patient-specific therapies to the bedside. The company’s Myoblast program is an autologous adult stem cell therapy for the treatment of heart disease. The Myoblast program has successfully completed four Phase I clinical trials and has clearance from the FDA to begin Phase II trials shortly. The company is also rapidly moving towards human clinical trials for its embryonic stem cell therapies including its RPE and HG programs. ACT published positive data from animal studies for its RPE (retinal pigment epithelial) cell program for the treatment of retinal degenerative disorders completed in collaboration with the Casey Eye Institute at Oregon Health and Science University. The company also has GLP Safety Studies in process for its RPE Program. ACT published positive data in the journal NATURE Methods for its HG (hemangioblast) cell program for the treatment of blood and cardiovascular diseases. The company expects to file INDs for its RPE and HG programs in 2008. In August 2006, ACT announced a novel technique to generate embryonic stem cell lines without destroying embryos, a breakthrough in the ethical debate surrounding the industry. Less than one year later, the company announced the creation of a human embryonic stem cell line without destroying the embryo. ACT owns or licenses over 380 patents and patent applications.

Click to Download our Company Presentation.

We are currently focused on three product areas.

1) Our myoblast program , which could yield novel therapies for cardiac diseases such as heart failure, successfully completed Phase I human clinical trials. The program has clearance from the FDA to begin Phase II human clinical trials and we expect to commence those trials shortly.

2) Our retinal pigment epithelium (RPE) program , which we believe could yield new therapies for treating indications such as age-related macular degeneration. We announced a collaboration to conduct preclinical trials and we expect to file an IND in 2008.

3) Our hemangioblast (HG) cell program for which we are currently conducting preclinical research programs investigating the possibility of using the cells to treat cardiovascular disease, stroke, and cancer. Our research, published in Nature Methods, demonstrated success in treating vascular indications such as heart attack and limb loss due to vascular damage. We expect to file an IND in 2008.

The company is led by an experienced management team and scientific experts in the field, including Chairman and CEO William M. Caldwell IV, VP of Research and Scientific Development Dr. Robert Lanza, and Chief Development Officer Dr. Pedro Huertas. The company operates GMP capable laboratories in Massachusetts California.

The company is actively pursuing strategic collaborations in the United States (e.g., in California, where in 2004, the state passed Proposition 71, often referred to as the “Stem Cell Initiative,” which will provide $3.0 billion of funding over the next ten years for stem cell research) and around the world with members of academia, industry and foundations to further accelerate the pace of our research efforts.

Investment Highlights
Completed acquisition of Mytogen and its Myoblast program, an autologous adult stem cell therapy for treating cardiac disease. The Myoblast program has successfully completed Phase I clinical trials. Expects to begin Phase II clinical trials shortly.
Published positive results from HG program demonstrating hemangioblasts’ ability to repair vascular damage in animals. Therapy could be effective for treatment of blood and cardiovascular diseases. Expects to file IND in 2008.
Made progress in macular degeneration indication by reporting positive data for RPE cell animal study. Entered into collaboration with the Casey Eye Institute to conduct preclinical trials. Expects to file IND in 2008.
Developed technique to generate embryonic stems that maintain developmental potential of the embryo and therefore has potential to shift the ethical debate. Announced hESC line created without destroying an embryo in June 2007.
Owns or licenses over 380 patents and patent applications related to stem cell therapy.
Large Target Market: Regenerative Medicine has potential to treat diseases of the eye, blood disorders, heart disease, neurodegenerative diseases, liver disease, diabetes, and others.
Led by experienced management team and scientific experts including CEO William Caldwell, VP of Research and Scientific Development, Robert Lanza M.D., and Chief Development Officer Pedro Huertas M.D.,Ph.D.
Growing Legislative Support
CA Prop. 71 provides $3.0 billion in funding over 10 years for stem cell research, with preference given to research that is ineligible for NIH funding.
Other states (e.g., NJ, CT, FL, IL, MD, NY, MA and MO) have passed or proposed similar initiatives.
New Congress elected 11/06 has promised to make stem cell research a priority. - this part needs work how bout a new administration! lol

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
BooDog
Member


Icon 1 posted      Profile for BooDog     Send New Private Message       Edit/Delete Post   Reply With Quote 
HEY IMAKE, DID YOU SEE THIS ONE????

getting closer...

http://money.cnn.com/2007/10/31/news/companies/stem_cells/index.htm?source=yahoo _quote

Next step in stem cells: Human tests
Companies are planning to submit applications for FDA approval to begin human testing of treatments based on embryonic stem cell research.
By Aaron Smith, CNNMoney.com staff writer
October 31 2007: 11:56 AM EDT


PITTSBURGH (CNNMoney.com) -- Companies that develop drugs using embryonic stem cell research could soon enter a bold new phase: human testing.

Geron Corp. and Advanced Cell Technology Inc. are preparing Food and Drug Administration applications to begin human testing of experimental treatments that are based on embryonic stem cells. If the companies get the go-ahead, they could begin tests as soon as next year.

More stem cell news...
Stem cells could treat diabetes
Stem cell industry set to break out
Rats walk but money waits
Video
More video
Esther Dyson of EDventure Holdings discusses how she thinks medical possibilities will broaden by making her own genetic code available on the web.
Play video
"What we're seeing now in the stem cell field is like a chess match," said Stephen Brozak, analyst for WBB Securities. "The early moves will ultimately dictate who succeeds in the stem cell space."

In the past, the FDA has approved human tests of products based on stem cells taken from adult tissue. But Geron and Advanced Cell Technologies could be the first to begin human testing of treatments based on the more controversial research using stem cells derived from embryos.

Human tests are the most advanced form of testing and one of the final hurdles before the FDA approves a drug.

Geron (Charts), based in Menlo Park, Calif., has been using rats in its experiments of a potential treatment for spinal cord injuries. Geron has already met with the FDA and will submit its plans for human testing to the agency by the end of this year, according to Sion Rogers, a spokesman for the company.

"We expect to be in the clinic [for human testing] next year," said Rogers.

Advanced Cell Technology (Charts) plans to submit its application for human testing to the FDA by the middle of next year, said Chief Executive Robert Lanza, who spoke at the 7th International Stem Cell Conference on Tuesday.

His company is developing potential treatments for vision loss diseases, including macular degeneration and Stargardt's, based on studies involving monkeys. If the treatment is successful, it would most likely compete with Genentech Inc.'s (Charts) vision loss treatment Lucentis, a fast-growing drug that had $600 million in sales during the first nine months of 2007.

Geron and Advanced Cell Technology are unlikely to compete with each other because their potential products are unrelated, said Ren Benjamin, analyst for Rodman & Renshaw.

"We think that it doesn't matter who gets to the clinic first, because the entire stem cell space will benefit when someone gets there," said Benjamin. "It will create a lot of excitement in investors, because it's a big milestone for the embryonic stem cell space."

Stem cells bring sight to the blind in India
The process of testing drugs on humans can take years to complete - in the case of drugs developed with human embryonic stem cells, a minimum of five years, said Lanza of Advanced Cell Technology. Typically, after studies are completed, an experimental drug is submitted to the FDA for review, a step that can take a minimum of six months to finish.

Small-scale biotech companies and universities have spearheaded embryonic stem-cell research in developing treatments for heart disease, diabetes, Parkinson's and injuries to the spine and brain.

Novocell Inc. also uses stem cells from human embryos for research, while other biotechs like Cytori Therapeutics (Charts) and Osiris Therapeutics, Inc. (Charts) use adult human tissue as a source.

Osiris, based in Columbia, Md., has the only stem cell-based product that has been approved by the FDA. The treatment, Osteocel, stimulates bone growth and is considered an implant, rather than a drug or device. The product was launched in 2005 and totaled about $5 million in sales during the first half of 2007, accounting for most of the company's revenue.

Companies that work with stem cells derived from adult tissue are insulated from the controversy surrounding embryonic stem cells. Many researchers prefer the use of human embryonic stem cells because they can rapidly reproduce themselves for years at a time in a lab environment.

But the use of embryonic stem cells, which are obtained through in vitro fertilization, is opposed by the pro-life contingent, including President George W. Bush. Bush has said that he opposes "the creation, destruction, or harming of living human embryos." Proponents of embryonic stem cells research dispute this notion, saying that the blastocysts used as sources for stem cells would otherwise be discarded as medical waste.

In 2001, Bush restricted federal funding for embryonic stem cell research to the stem cell lines that existed at the time, and in June 2007 vetoed a Congressional bill to lift these restrictions. The presidential lines, as they are called, represent only about 5 percent of the stem cells available in the world today, according to Dr. James Battey Jr., co-chair of the stem cell task force for the National Institutes of Health.

Novocell, a privately-held biotech based in San Diego, uses embryonic stem cell research in developing treatments for diabetes. Chief Executive Alan Lewis said that he is a couple of years behind Geron and Advanced Cell Technologies, and he is yet to finish studies using mice.

"The study needs to be completed before we got out and bang a drum and talk about curing diabetes," said Lewis.

The analysts interview for this story do not own stock in the companies mentioned here, and their firms have not conducted business with the companies within the last 12 months.

Stem cells could treat diabetes

someone's putting fresh coals in the fire eh??

--------------------
All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?

Posts: 7800 | From: Virginia | Registered: May 2006  |  IP: Logged | Report this post to a Moderator
Lani
New Member


Rate Member
Icon 1 posted      Profile for Lani     Send New Private Message       Edit/Delete Post   Reply With Quote 
Could anyone please give me a list of websites where I could get statistics for daily price list on OTCBB stocks? I'm a beginner in this business!
My e-mail address is: ifetoba2001*yahoo.com

Posts: 1 | From: New York | Registered: Oct 2007  |  IP: Logged | Report this post to a Moderator
  This topic comprises 8 pages: 1  2  3  4  5  6  7  8   

Quick Reply
Message:

HTML is enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share